All lobbying filings

WINNING STRATEGIES WASHINGTON

WINNING STRATEGIES WASHINGTON filed a Q3 report for MASS GENERAL BRIGHAM on October 20, 2026, reporting $30,000 in lobbying income.

Lobbying for MASS GENERAL BRIGHAM · Integrated Healthcare System

All filings by WINNING STRATEGIES WASHINGTON · Everything MASS GENERAL BRIGHAM has reported

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 20, 2026.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$30,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 4

MICHAEL A MEROLA

Previously held: Deputy CoS, Sen. Torricelli
DONNA MULLINS

Previously held: CoS/Approps Staff, Rep. Frelinghuysen and Rep. Dean Gallo; CoS Senator Chiesa
JAMIE ROBINETTE

Previously held: COS, Rep. Aaron Bean; ED/LD, Rep. Ann Wagner (R-MO); Senior Advisor, Rep. Neal Dunn (R-FL); COS Rep. Ross Spano (R-FL); COS, Rep. John Culberson (R-TX)
BRYAN RICKER

Previously held: Regional Director, Sen. Crapo

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Funding for the treatment of non-communicable diseases in Sub-Saharan Africa, including Type 1 diabetes, rheumatic and congenital heart disease, and sickle cell disease; monitoring changes to the Administration and focus of US humanitarian assistance programs

Foreign Relations

Funding for the treatment of non-communicable diseases in Sub-Saharan Africa including Type 1 diabetes, rheumatic and congenital heart disease, and sickle cell disease; monitoring changes to the Administration and focus of US humanitarian assistance programs

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.